04:25 PM EDT, 10/14/2025 (MT Newswires) -- Bristol Myers Squibb ( BMY ) and insitro said late Tuesday they are extending their partnership for new molecules with potential as new therapies for amyotrophic lateral sclerosis.

The partnership will leverage insitro's ChemML platform to design new medicines for a novel ALS target that was found in the first evaluation phase and may provide up to $20 million in new funding for the one-year extension, they said.

The collaboration extension builds on a 5-year agreement announced in 2020, the companies said.